Panayiotis Panayiotidis

7PUBLICATIONS
59CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 16, 2026
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

|Feb 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Nov 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Mar 04, 2024
The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.

Sevastianos Chatzidavid, Christina-Nefeli Kontandreopoulou, Nefeli Giannakopoulou

|Jan 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.

Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström

|Sep 16, 2022
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

Pageof 2

Frequent Collaborators

3 joint publications

Vladimir Ivanov

3 joint publications

Yan Sun

3 joint publications

Pau Montesinos

3 joint publications

Courtney D DiNardo